Elizabeth Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elizabeth Chan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amit Achhra
Section of Infectious Diseases, Department of Medicine, Yale School of Medicine , New Haven, Connecticut
2 shared publications - Lydia Aoun Barakat
Section of Infectious Diseases, Department of Medicine, Yale School of Medicine , New Haven, Connecticut
2 shared publications - Michael Virata
Section of Infectious Diseases, Department of Medicine, Yale School of Medicine , New Haven, Connecticut
2 shared publications Ritche Hao
Section of Infectious Diseases, Department of Medicine, Yale School of Medicine , New Haven, Connecticut
2 shared publications- Serina S. Applebaum
Section of Infectious Diseases, Department of Medicine, Yale School of Medicine , New Haven, Connecticut
2 shared publications - Haddon Pantel
Department of Surgery, Yale School of Medicine, New Haven, Connecticut
1 shared publication
Latest Publications
- Open Access
- 10 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Evaluation of Anal Cancer Screening Among 18-to-34-Year-Old Men Who Have Sex With Men Living With HIV Over a 10-Year Period
Guidelines now support anal squamous cell carcinoma (ASCC) screening in men who have sex with men (MSM) living with HIV (LWH) aged ≥35 years. There is limited data on screening in MSM LWH <35 years. Two academic HIV clinics in the Northeastern US. We retrospectively evaluated all anal cytology and high-resolution anoscopy (HRA; referral criteria: atypical cells of undetermined significance [ASC-US] or worse cytology) performed for MSM LWH between ages 18–34 from 2013 to 2023. We evaluated risk factors for abnormal cytology or histology, and prevalence of high-grade dysplasia (HSIL) and ASCC. Of 216 eligible MSM LWH, 111 (51%) were screened for ASCC at least once. Screened individuals had longer follow-up (median 4.0 vs 1.6 years) but were otherwise similar to unscreened individuals. Among 246 cytology tests, 19% were unsatisfactory and 31% abnormal, of which 1.2% reported HSIL. Of 23 HRAs following abnormal cytology, 10 (43%) revealed HSIL. Testing in response to symptoms was associated with abnormal results (OR 8.54; 95% CI 2.55–28.67). Human papillomavirus vaccination trended toward protection against abnormal results. We identified two cases of local ASCC, both in individuals with symptomatic condyloma and severe immunosuppression. Over 10 years, ASCC screening in MSM LWH <35 years was variable. Anal cytology had high unsatisfactory rates and poor correlation with histology. Despite high dysplasia prevalence among those undergoing HRA, ASCC was rare and diagnosed early from symptoms. Findings support excluding younger (≤34 years) MSM LWH from asymptomatic screening, and support symptom-driven testing to diagnose anal cancer early.
- 10 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Open AccessEvaluation of Anal Cancer Screening Among 18-to-34-Year-Old Men Who Have Sex With Men Living With HIV Over a 10-Year Period
Guidelines now support anal squamous cell carcinoma (ASCC) screening in men who have sex with men (MSM) living with HIV (LWH) aged ≥35 years. There is limited data on screening in MSM LWH <35 years. Two academic HIV clinics in the Northeastern US. We retrospectively evaluated all anal cytology and high-resolution anoscopy (HRA; referral criteria: atypical cells of undetermined significance [ASC-US] or worse cytology) performed for MSM LWH between ages 18–34 from 2013 to 2023. We evaluated risk factors for abnormal cytology or histology, and prevalence of high-grade dysplasia (HSIL) and ASCC. Of 216 eligible MSM LWH, 111 (51%) were screened for ASCC at least once. Screened individuals had longer follow-up (median 4.0 vs 1.6 years) but were otherwise similar to unscreened individuals. Among 246 cytology tests, 19% were unsatisfactory and 31% abnormal, of which 1.2% reported HSIL. Of 23 HRAs following abnormal cytology, 10 (43%) revealed HSIL. Testing in response to symptoms was associated with abnormal results (OR 8.54; 95% CI 2.55–28.67). Human papillomavirus vaccination trended toward protection against abnormal results. We identified two cases of local ASCC, both in individuals with symptomatic condyloma and severe immunosuppression. Over 10 years, ASCC screening in MSM LWH <35 years was variable. Anal cytology had high unsatisfactory rates and poor correlation with histology. Despite high dysplasia prevalence among those undergoing HRA, ASCC was rare and diagnosed early from symptoms. Findings support excluding younger (≤34 years) MSM LWH from asymptomatic screening, and support symptom-driven testing to diagnose anal cancer early.
- Open Access
- 4 November 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (5) , 1133-1138
Five-Year Evaluation of an Anal Cancer Screening Program in Men Who Have Sex With Men With HIV at 2 Academic Center Clinics
Background: Guidelines recommend annual anal cytology-based squamous cell carcinoma of anus (SCCA) screening for men who have sex with men with HIV aged ≥35 years (eligible population). The recommended threshold for high-resolution anoscopy (HRA) depends on its availability: low-threshold (any abnormal cytology) if availability is high and high-threshold (high-grade squamous intraepithelial lesion [HSIL] on cytology) if availability is low. Methods: This was a retrospective chart review (2018–2022) at academic HIV clinics. We evaluated (1) 5-year uptake of cytology-based SCCA screening in the eligible population and (2) estimated HSIL detection rate based on our current low-threshold criteria, and if high-threshold criteria were used for HRA referral. Results: Of 432 eligible individuals, only 219 (50.7%) had at least 1 and only 113 (26%) had >1 SCCA screening tests in a median follow-up of 4 years. Seventy-four (17.1%) individuals had at least 1 abnormal anal cytology during follow-up, of whom 56 (75.6%) underwent HRA. Increasing age (≥57 years) and history of smoking negatively correlated with ever receiving screening. Anal cytology (365 tests in 206 individuals) showed 17.5% “unsatisfactory” and 26.8% with any abnormal cytology (zero with HSIL) triggering HRA referral. Only 34 individuals (7.8% of screening eligible) were ever detected with HSIL. Strictly using high-threshold criteria for HRA referral would have led to no HRA or HSIL detection. Conclusions: We noted poor uptake of screening over time, particularly in older age groups. Importantly, anal cytology performed poorly as a triage test for HRA referral, with high rates of “unsatisfactory” samples and low sensitivity for detecting HSIL.
- 4 November 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (5) , 1133-1138
Open AccessFive-Year Evaluation of an Anal Cancer Screening Program in Men Who Have Sex With Men With HIV at 2 Academic Center Clinics
Background: Guidelines recommend annual anal cytology-based squamous cell carcinoma of anus (SCCA) screening for men who have sex with men with HIV aged ≥35 years (eligible population). The recommended threshold for high-resolution anoscopy (HRA) depends on its availability: low-threshold (any abnormal cytology) if availability is high and high-threshold (high-grade squamous intraepithelial lesion [HSIL] on cytology) if availability is low. Methods: This was a retrospective chart review (2018–2022) at academic HIV clinics. We evaluated (1) 5-year uptake of cytology-based SCCA screening in the eligible population and (2) estimated HSIL detection rate based on our current low-threshold criteria, and if high-threshold criteria were used for HRA referral. Results: Of 432 eligible individuals, only 219 (50.7%) had at least 1 and only 113 (26%) had >1 SCCA screening tests in a median follow-up of 4 years. Seventy-four (17.1%) individuals had at least 1 abnormal anal cytology during follow-up, of whom 56 (75.6%) underwent HRA. Increasing age (≥57 years) and history of smoking negatively correlated with ever receiving screening. Anal cytology (365 tests in 206 individuals) showed 17.5% “unsatisfactory” and 26.8% with any abnormal cytology (zero with HSIL) triggering HRA referral. Only 34 individuals (7.8% of screening eligible) were ever detected with HSIL. Strictly using high-threshold criteria for HRA referral would have led to no HRA or HSIL detection. Conclusions: We noted poor uptake of screening over time, particularly in older age groups. Importantly, anal cytology performed poorly as a triage test for HRA referral, with high rates of “unsatisfactory” samples and low sensitivity for detecting HSIL.